Eli Lilly and Company (NYSE:LLY) Shares Purchased by Relyea Zuckerberg Hanson LLC

Relyea Zuckerberg Hanson LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 3,033 shares of the company’s stock after buying an additional 323 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Eli Lilly and Company were worth $2,342,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. CNB Bank increased its stake in Eli Lilly and Company by 10.1% during the 4th quarter. CNB Bank now owns 1,255 shares of the company’s stock valued at $969,000 after buying an additional 115 shares during the period. Avanza Fonder AB acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $2,316,000. Procyon Advisors LLC grew its stake in shares of Eli Lilly and Company by 11.9% in the 4th quarter. Procyon Advisors LLC now owns 3,942 shares of the company’s stock worth $3,043,000 after purchasing an additional 419 shares during the last quarter. Everpar Advisors LLC grew its stake in shares of Eli Lilly and Company by 0.6% in the 4th quarter. Everpar Advisors LLC now owns 2,680 shares of the company’s stock worth $2,069,000 after purchasing an additional 17 shares during the last quarter. Finally, Tompkins Financial Corp grew its stake in shares of Eli Lilly and Company by 7.4% in the 4th quarter. Tompkins Financial Corp now owns 33,270 shares of the company’s stock worth $25,684,000 after purchasing an additional 2,288 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Barclays lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Finally, Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Price Performance

Shares of LLY opened at $726.24 on Friday. The firm has a market cap of $689.43 billion, a PE ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41. The firm’s 50 day moving average price is $781.14 and its 200 day moving average price is $854.71. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a twelve month low of $612.70 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. As a group, research analysts expect that Eli Lilly and Company will post 13.14 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has approved a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.